News

Six partners seek kinase drugs
Enlarge image

ResearchEU

Six partners seek kinase drugs

11.04.2013 - Fuelled by €1.1m of EU money, six European partners from industry and academia plan to find kinase-targeting drugs in a venture called TAKTIC.

A focussed group of three SMEs and three academic partners form the Translational Kinase Tumour Inhibitor Discovery Consortium (TAKTIC). Members announced on 10 April the creation of the consortium which is financed to the tune of €1.1m by the EU’s 7th Framework Programme “Research for the Benefit of SMEs”. The industry partners comprise SARomics Biostructures from Lund (Sweden), Prestwick Chemical from Illkirch (France) and ProQinase GmbH from Freiburg (Germany). The collaborating academic scientists work at the University of Turin (Italy) the Israel Structural Proteomics Center (ISPC) at the Weizmann Institute of Science and the TechMedIll platform of the University of Strasbourg (France).

Targeting kinases has become one of the most important therapeutic opportunities for treating cancer, diabetes, inflammatory diseases and more. The TAKTIC Consortium offers its members extensive expertise in medicinal chemistry, kinase biochemistry as well as state-of-the-art high-throughput platforms for protein expression and crystallisation. The merging of the highly complementary capabilities of the six partners within TAKTIC enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases, the partners said in a joint press release.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-02/six-partners-seek-kinase-drugs.html

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.40 EUR11.63%
  • SARTORIUS113.95 EUR4.93%
  • EVONIK27.85 EUR3.69%

FLOP

  • ADDEX3.30 CHF-4.07%
  • BIOFRONTERA1.95 EUR-3.47%
  • MEDIGENE3.70 EUR-2.63%

TOP

  • CYTOS0.33 CHF43.5%
  • ADDEX3.30 CHF42.2%
  • FORMYCON14.30 EUR41.9%

FLOP

  • BIOFRONTERA1.95 EUR-15.2%
  • ACTELION100.20 CHF-13.8%
  • MOLOGEN5.60 EUR-11.8%

TOP

  • SANTHERA105.50 CHF2557.4%
  • BB BIOTECH256.75 EUR102.4%
  • FORMYCON14.30 EUR90.7%

FLOP

  • CYTOS0.33 CHF-90.9%
  • MOLOGEN5.60 EUR-51.5%
  • 4SC0.82 EUR-50.0%

No liability assumed, Date: 28.01.2015